BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.